Approval · Notice of Compliance 2205 · 2001
VIDEX EC: Notice of Compliance 2205
Issued October 4, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2205
- Date
- October 4, 2001
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To gain approval for a new encapsulated enteric-coated beadlet formulation as well as a once-daily dosage administration
- Therapeutic class
- Antiretroviral agent
Products in this notice
Medicinal ingredients
- DIDANOSINE 125 MG per CAP
- DIDANOSINE 200 MG per CAP
- DIDANOSINE 250 MG per CAP
- DIDANOSINE 400 MG per CAP